Effect of TNF alpha inhibitors on atherosclerosis in psoriatic arthritis patients: a systematic review protocol

##plugins.themes.academic_pro.article.sidebar##

Published Aug 22, 2025
https://doi.org/10.62438/tunismed.v103i8.5595
Download
Vol. 103 No. 8 (2025): Tunis Med Aug 2025

##plugins.themes.academic_pro.article.main##

Yasmine Makhlouf
Department of rheumatology, Mongi Slim Hospital
Dr Hiba Boussaa
Department of rheumatology, Mongi Slim Hospital
Dr Hiba Bettaieb
Department of Internal Medicine, Internal Forces Security Hospital
Dr Alia Fazaa
Department of rheumatology, Mongi Slim Hospital
Dr Ismail Dergaa
Department of rheumatology, Mongi Slim Hospital
Dr Manel Boudokhane
Department of Internal Medicine Department, Internal Forces Security Hospital
Dr Mohamed Hedi Douggui
Department of Internal Medicine Department, Internal Forces Security Hospital, La marsa,
Dr Syrine Bellakhal
Department of Internal Medicine Department, Internal Forces Security Hospital, La marsa,
Dr Kawther Ben Abdelghani
Department of rheumatology, Mongi Slim Hospital
Dr Saoussen Miladi
Department of rheumatology, Mongi Slim Hospital
Dr Ahmed Laatar
Department of rheumatology, Mongi Slim Hospital

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by joint pain, stiffness, and swelling with typical skin manifestations of psoriasis. Chronic inflammation is a major cause of endothelial dysfunction, and atherosclerosis. In this optic, we conducted a systematic review of the literature to provide the most-up-to date literature regarding the effect of TNF alpha inhibitors on atherosclerosis in psoriatic arthritis patients. This systematic review was registered in prospero: CRD42023451234. We will follow the PRISMA guidelines and the search will be carried out using Pubmed, Scopus, Embase and Cochrane Library from inception until September 3th /2024. The search strategy, literature selection, and data extraction will be conducted independently by two investigator using a pre-piloted data extraction form. potential biases will be assessed using Newcastle Ottawa Scale (NOS) for the cohort and case control studies and the revised Cochrane risk-of-bias tool for randomized trials . Only studies that met high quality will belong to our final selection. The results will be publicly available and published in a peer-reviewed journal.

Keywords:

TNF alpha inhibitors, endothelial dysfunction, psoriatic arthritis, atherosclerosis

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. (1) Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692.
  2. (2) Garshick MS, Ward NL, et al. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(13):1670-80.
  3. (3) Ursini F, Leporini C, et al. Anti-TNF-alpha agents and endothelial function
  4. in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep. 2017;7(1):5346.
  5. (4) Brezinski EA, Follansbee MR, et al. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des.
  6. ;20(4):513-28.
  7. (5) Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
  8. (6) Sterne JAC, Savović J, Page MJ, Elbers G, Blencowe NS2, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
  9. (7) Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5.